Evaluation of the efficacy of tongue-lip adhesion in Pierre Robin sequence. En savoir plus sur Evaluation of the efficacy of tongue-lip adhesion in Pierre Robin sequence.
Validation of the grown-ups with congenital heart disease score. En savoir plus sur Validation of the grown-ups with congenital heart disease score.
Clinical Outcomes of Single Anteromedial Bundle Biologic Augmentation Technique for Anterior Cruciate Ligament Reconstruction With Consideration of Tibial Remnant Size. En savoir plus sur Clinical Outcomes of Single Anteromedial Bundle Biologic Augmentation Technique for Anterior Cruciate Ligament Reconstruction With Consideration of Tibial Remnant Size.
Reaching low-density lipoprotein cholesterol treatment targets in stable coronary artery disease: Determinants and prognostic impact. En savoir plus sur Reaching low-density lipoprotein cholesterol treatment targets in stable coronary artery disease: Determinants and prognostic impact.
High Risk of Anal and Rectal Cancer in Patients With Anal and/or Perianal Crohn''s Disease. En savoir plus sur High Risk of Anal and Rectal Cancer in Patients With Anal and/or Perianal Crohn''s Disease.
Radiological evaluation of scapholunate intercarpal ligamentoplasty for chronic scapholunate dissociation in cadavers. En savoir plus sur Radiological evaluation of scapholunate intercarpal ligamentoplasty for chronic scapholunate dissociation in cadavers.
Soft Tissue Masses of the Knee Related to a Focal Defect of the Lateral Patellar Retinaculum. En savoir plus sur Soft Tissue Masses of the Knee Related to a Focal Defect of the Lateral Patellar Retinaculum.
Rituximab for corticosteroid-resistant relapsing IgG4-related intracranial pachymeningitis: report of two cases. En savoir plus sur Rituximab for corticosteroid-resistant relapsing IgG4-related intracranial pachymeningitis: report of two cases.
An oligoclonal antibody durably overcomes resistance of lung cancer to third-generation EGFR inhibitors. En savoir plus sur An oligoclonal antibody durably overcomes resistance of lung cancer to third-generation EGFR inhibitors.